ESPE Abstracts (2015) 84 P-2-425

ESPE2015 Poster Category 2 GH & IGF (40 abstracts)

Comparison of Baseline Parameters and Response to GH Treatment in 125 Children with Short Stature with Eight Different Diagnosis

Irene Ioimo , Alessandro Mussa , Silvia Vannelli , Francesca Feyles , Silvia Einaudi & Patrizia Matarazzo


Regina Margherita Children Hospital, Città della Salute, Torino, Italy

Background: Response to rhGH treatment is variable among GH deficiency (GHD), GH insensitivity and several intermediate conditions.

Aims and objectives: To compare baseline parameters and response to rhGH treatment in eight diagnostic categories of patients with short stature.

Methods: We selected 125 prepubertal children presenting at least 2 years of rhGH treatment (mean 5.29 years, range 2–15.6 years), hormonal and clinic parameters alterations (0<IGF1 <−2 SDS and/or GH stimulated peak secretion <8 μg/l and H<−3 SDS or HV <−2 SDS or H<−2 SDS+HV<−1.5 SDS). We divided patients in eight groups: 19 organic-GHD (GHD-O), 19 isolated idiopathic-GHD (GHD-II), 16 neuroscretory dysfunction (NSD), 14 radio-treated-GHD patients (rt-GHD), 15 ISS, 11 SGA, 11 SHOX-Deficiency, 20 Turner syndrome (TS). Changes in height and in height velocity SDS at 1 year and at the last visit were evaluated in relation to years of treatment and average doses of rhGH.

Results: At the 1st year all groups gained >1 height SDS. At the last visit, GHD-O gain 1.78±1.58 SDS, SGA 1.07±0.4 SDS, NSD 0.90±0.65 SDS, ISS 0.84±0.66 SDS, GHD-II 0.72±0.55 SDS, SHOX-D 0.72±0.49 SDS, TS 0.23±0.61 SDS, rt-GHD 0.05±1.84 SDS. Statistical significant differences in height gain SDS at the last visit were found between: GHD-O vs rt-GHD (P 0.0014); GHD-O vs GHD-II (P 0.0246); rt-GHD vs GHD-II (P 0.0154); rt-GHD vs NSD (P 0.0112); SHOX-D vs TS (P 0.0318), while was not found between GHD-II vs BSI (P 0.3228).

Conclusions: rhGH treatment improves the short-term response in all groups and the long-term response in most patients: GHDO has the better response, radio-treated patients have the lowest, GHDII and ISS intermediate comparable response. Our data indicate that it is better review periodically the selection criteria and response to treatment.

Article tools

My recent searches

No recent searches.